P. Jaiprasart

Identification of signature genes associated with therapeutic resistance to anti-VEGF therapy

S. Woo, S. Dogra, B. Devapatla, 2020, Oncotarget.

Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex

Bertrand Z. Yeung, J. Au, Ze Lu, 2018, Journal of controlled release : official journal of the Controlled Release Society.

Translational PK/PD and model‐informed development of JNJ‐67842125, a Fab reversal agent for JNJ‐64179375, a long‐acting thrombin inhibitor

Brian J. Geist, M. Chintala, Weirong Wang, 2021, British journal of pharmacology.

Development of a Minimal Physiologically-Based Pharmacokinetic/ Pharmacodynamic Model to Characterize Target Cell Depletion and Cytokine Release for T Cell-Redirecting Bispecific Agents in Humans.

Weirong Wang, Xi Chen, Xiling Jiang, 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis

R. Janknecht, Resham Bhattacharya, K. Ding, 2019, Molecular Cancer Research.

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer.

N. Agarwal, E. Attiyeh, A. Hansen, 2023, Clinical genitourinary cancer.

Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).

N. Agarwal, E. Attiyeh, A. Hansen, 2022, Journal of Clinical Oncology.